ZBP1 PROTAC-1
ZBP1 PROTAC-1 is a PROTAC degrader targeting ZBP1, with a DC50 of 81.52 nM. ZBP1 PROTAC-1 uses a DNA aptamer to specifically bind ZBP1, recruits the VHL E3 ubiquitin ligase, and induces ZBP1 degradation via the ubiquitin-proteasome pathway. ZBP1 PROTAC-1 can partially restore the viability of H1N1-infected cells. ZBP1 PROTAC-1 can be used in studies related to viral pneumonia and influenza A H1N1 virus infection.
(Pink: Target protein ligand; Blue: VHL ligand (HY-125845); Black: linker).
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All PROTACs Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
ZBP1 81.52 nM (DC50) |
VHL |
In Vitro
ZBP1 PROTAC-1 (2a+aptamer) (100 nM) restores cell viability from 34.9% to 65.2% in H1N1-infected A549 cells[1].
ZBP1 PROTAC-1 (12.5-200 nM; 0-48 h) induces concentration-dependent degradation of ZBP1 in cells with CBL0137 (HY-18935)-induced ZBP1 overexpression, with a DC50 of 81.52 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Cells pre-treated with CBL0137 to upregulate ZBP1
-
Concentration:12.5, 25, 50, 100 and 200 nM
-
Incubation Time:0, 6, 12, 24, 36 and 48 h
-
Result:In CBL0137-induced ZBP1-overexpressing cells, ZBP1 was degraded in a concentration-dependent manner, with a DC50 of 81.52 nM.
Chemical Information
-
SMILES
O=C(CCCCC(N[3'-AAGTGCCATCGTGCGTATCCCTCGCGTCTGCTTGCTC GTCCCAACCCACCACCGCCCGATACGCACCTCACGACHTT-5'])=O)N1C2=C(C3=C(C4=C(C1)C=CC=C4)N(CCOCCOCCOCC(N[C@@H](C(C)(C)C)C(N5C[C@@H](C[C@H]5C(NCC6=CC=C(C7=C(C)N=CS7)C=C6)=O)O)=O)=O)N=N3)C=CC=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)